Literature DB >> 17417741

Modification of L-DOPA pharmacological activity by MAO inhibitors.

J P M Finberg1, O Sader-Mazbar.   

Abstract

Dopamine behaves mainly as a MAO-A substrate in rodent brain, but selective inhibition of MAO-B results in an increased turning activity following L-DOPA administration in hemi-Parkinsonian rodents. Unilateral substantia nigra dopaminergic denervation results in serotonergic hyper-innervation which may increase the contribution of MAO-A in the denervated striatum. Possibly as a result of this, there was no change in striatal MAO-A activity when 95% of dopaminergic innervation was reduced by 6-hydroxydopamine, as assessed by apomorphine-induced turning activity. MAO-B as well as MAO-A may contribute to deamination of dopamine produced from L-DOPA.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17417741     DOI： 10.1007/s00702-007-0691-y

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN： 0300-9564            Impact factor:   3.575


  40 in total

1.  A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.

Authors: 
Journal:  Arch Neurol       Date:  2002-12

Review 2.  Levodopa in the treatment of Parkinson's disease: current controversies.

Authors:  C Warren Olanow; Yves Agid; Yoshi Mizuno; Alberto Albanese; Ubaldo Bonuccelli; U Bonucelli; Philip Damier; Justo De Yebenes; Oscar Gershanik; Mark Guttman; F Grandas; Mark Hallett; Ole Hornykiewicz; Peter Jenner; R Katzenschlager; William J Langston; Peter LeWitt; Eldad Melamed; M A Mena; P P Michel; Catherine Mytilineou; Jose A Obeso; Werner Poewe; Niall Quinn; R Raisman-Vozari; Ali H Rajput; Olivier Rascol; Christina Sampaio; Fabrizio Stocchi
Journal:  Mov Disord       Date:  2004-09       Impact factor: 10.338

3.  Inhibition of MAO-B by (-)-deprenyl alters dopamine metabolism in the macaque (Macaca facicularis) brain.

Authors:  I A Paterson; B A Davis; D A Durden; A V Juorio; P H Yu; G Ivy; W Milgram; A Mendonca; P Wu; A A Boulton
Journal:  Neurochem Res       Date:  1995-12       Impact factor: 3.996

4.  Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys.

Authors:  D A Di Monte; L E DeLanney; I Irwin; J E Royland; P Chan; M W Jakowec; J W Langston
Journal:  Brain Res       Date:  1996-10-28       Impact factor: 3.252

5.  Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats.

Authors:  J P Finberg; J Wang; D S Goldstein; I J Kopin; K S Bankiewicz
Journal:  J Neurochem       Date:  1995-09       Impact factor: 5.372

6.  In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism.

Authors:  T Brannan; A Prikhojan; J Martínez-Tica; M D Yahr
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1995

7.  Effect of selegiline on dopamine concentration in the striatum of a primate.

Authors:  S Kaseda; M Nomoto; S Iwata
Journal:  Brain Res       Date:  1999-01-02       Impact factor: 3.252

8.  Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.

Authors:  I Lamensdorf; M B Youdim; J P Finberg
Journal:  J Neurochem       Date:  1996-10       Impact factor: 5.372

9.  The site of dopamine formation in rat striatum after L-dopa administration.

Authors:  F Hefti; E Melamed; R J Wurtman
Journal:  J Pharmacol Exp Ther       Date:  1981-04       Impact factor: 4.030

10.  L-DOPA increases noradrenaline turnover in central and peripheral nervous systems.

Authors:  Lior Dayan; John P M Finberg
Journal:  Neuropharmacology       Date:  2003-09       Impact factor: 5.250
View more
  2 in total

1.  Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson's Disease with Neuroprotective Potential.

Authors:  John P M Finberg
Journal:  Rambam Maimonides Med J       Date:  2010-07-02

2.  From a Parkinson's disease expert: Rasagiline and the future of therapy.

Authors:  Shaheen E Lakhan
Journal:  Mol Neurodegener       Date:  2007-07-06       Impact factor: 14.195
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.